Water-soluble prodrugs of dipeptide HIV protease inhibitors based on O→N intramolecular acyl migration:: design, synthesis and kinetic study

被引:36
作者
Hamada, Y [1 ]
Matsumoto, H [1 ]
Yamaguchi, S [1 ]
Kimura, T [1 ]
Hayashi, Y [1 ]
Kiso, Y [1 ]
机构
[1] Kyoto Pharmaceut Univ, Ctr Frontier Res Med Sci, Dept Med Chem, Yamashima Ku, Kyoto 6078412, Japan
关键词
HIV-1; protease; O -> N; intramolecular acyl migration; HIV protease inhibitor; water-soluble prodrug;
D O I
10.1016/j.bmc.2003.10.026
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
To improve the low water-solubility of HIV protease inhibitors, we synthesized water-soluble prodrugs of KNI-727, a potent small-sized dipeptide-type HIV-1 protease inhibitor consisting of an Apns-Dmt core (Apns; allophenylnorstatine, Dmt; (R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid) as inhibitory machinery. These prodrugs contained an O-acyl peptidomimetic structure with an ionized amino group leading to an increase in water-solubility, and were designed to regenerate the corresponding parent drugs based on the O --> N intramolecular acyl migration reaction via a five-membered ring intermediate at the alpha-hydroxy-beta-amino acid residue, that is Apns. The synthetic prodrug 3a improved the water-solubility (13 mg/mL) more than 8000-fold in comparison with the parent compound, which is the practically acceptable value as water-soluble drug. Furthermore, to understand the structural effects of the O-acyl moiety on the migration rate, we evaluated several phenylacetyl-type and benzoyl-type prodrugs. These prodrugs were stable as an HCl salt and in a strongly acidic solution corresponding to gastric juice (pH 2.0), and could be converted to the parent compounds promptly under aqueous conditions from slightly acidic to basic pH at 37 degreesC. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:159 / 170
页数:12
相关论文
共 46 条
[11]   INVITRO ANTI-HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) ACTIVITIES OF TRANSITION-STATE MIMETIC HIV PROTEASE INHIBITORS CONTAINING ALLOPHENYLNORSTATINE [J].
KAGEYAMA, S ;
MIMOTO, T ;
MURAKAWA, Y ;
NOMIZU, M ;
FORD, H ;
SHIRASAKA, T ;
GULNIK, S ;
ERICKSON, J ;
TAKADA, K ;
HAYASHI, H ;
BRODER, S ;
KISO, Y ;
MITSUYA, H .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (04) :810-817
[12]  
KATAOKA H, 1989, CHEM PHARM BULL, V37, P3166
[13]   Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy [J].
Kempf, DJ ;
Sham, HL ;
Marsh, KC ;
Flentge, CA ;
Betebenner, D ;
Green, BE ;
McDonald, E ;
Vasavanonda, S ;
Saldivar, A ;
Wideburg, NE ;
Kati, WM ;
Ruiz, L ;
Zhao, C ;
Fino, LM ;
Patterson, J ;
Molla, A ;
Plattner, JJ ;
Norbeck, DW .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (04) :602-617
[14]   ABT-538 IS A POTENT INHIBITOR OF HUMAN-IMMUNODEFICIENCY-VIRUS PROTEASE AND HAS HIGH ORAL BIOAVAILABILITY IN HUMANS [J].
KEMPF, DJ ;
MARSH, KC ;
DENISSEN, JF ;
MCDONALD, E ;
VASAVANONDA, S ;
FLENTGE, CA ;
GREEN, BE ;
FINO, L ;
PARK, CH ;
KONG, XP ;
WIDEBURG, NE ;
SALDIVAR, A ;
RUIZ, L ;
KATI, WM ;
SHAM, HL ;
ROBINS, T ;
STEWART, KD ;
HSU, A ;
PLATTNER, JJ ;
LEONARD, JM ;
NORBECK, DW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (07) :2484-2488
[15]   CRYSTAL-STRUCTURE OF HIV-1 PROTEASE IN COMPLEX WITH VX-478, A POTENT AND ORALLY BIOAVAILABLE INHIBITOR OF THE ENZYME [J].
KIM, EE ;
BAKER, CT ;
DWYER, MD ;
MURCKO, MA ;
RAO, BG ;
TUNG, RD ;
NAVIA, MA .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1995, 117 (03) :1181-1182
[16]  
KIMURA T, 1995, PEPTIDE CH, P157
[17]  
Kiso Y, 1999, BIOPOLYMERS, V51, P59, DOI 10.1002/(SICI)1097-0282(1999)51:1<59::AID-BIP7>3.0.CO
[18]  
2-3
[19]   Design of small peptidomimetic HIV-1 protease inhibitors and prodrug forms [J].
Kiso, Y ;
Matsumoto, H ;
Yamaguchi, S ;
Kimura, T .
LETTERS IN PEPTIDE SCIENCE, 1999, 6 (5-6) :275-281
[20]  
Kiso Y, 1998, ARCH PHARM, V331, P87, DOI 10.1002/(SICI)1521-4184(199803)331:3<87::AID-ARDP87>3.0.CO